

# Nicola Sgherza

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/213720/publications.pdf>

Version: 2024-02-01

63  
papers

865  
citations

471509

17  
h-index

526287

27  
g-index

63  
all docs

63  
docs citations

63  
times ranked

1394  
citing authors

#	ARTICLE	IF	CITATIONS
1	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. <i>Cancer</i> , 2020, 126, 1243-1252.	4.1	106
2	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. <i>Frontiers in Oncology</i> , 2018, 8, 194.	2.8	84
3	Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice. <i>Haematologica</i> , 2019, 104, 1589-1596.	3.5	58
4	Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. <i>Hematological Oncology</i> , 2019, 37, 296-302.	1.7	53
5	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. <i>Hematological Oncology</i> , 2018, 36, 561-569.	1.7	46
6	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. <i>Haematologica</i> , 2013, 98, 399-403.	3.5	42
7	Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. <i>Annals of Hematology</i> , 2018, 97, 1577-1580.	1.8	32
8	Efficacy and safety of ruxolitinib in intermediate- and high-risk myelofibrosis patients: Results from an independent study. <i>Hematological Oncology</i> , 2018, 36, 285-290.	1.7	29
9	Flow Cytometry Assessment of CD26 + Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia. <i>Cytometry Part B - Clinical Cytometry</i> , 2019, 96, 294-299.	1.5	28
10	Challenges and Opportunities of MicroRNAs in Lymphomas. <i>Molecules</i> , 2014, 19, 14723-14781.	3.8	26
11	Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis. <i>American Journal of Hematology</i> , 2018, 93, E159-E161.	4.1	26
12	Frontline Dasatinib Treatment in a Real-Life Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. <i>Neoplasia</i> , 2016, 18, 536-540.	5.3	24
13	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study. <i>Seminars in Hematology</i> , 2018, 55, 248-255.	3.4	24
14	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. <i>Leukemia Research</i> , 2018, 74, 86-88.	0.8	23
15	Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors. <i>International Journal of Cardiology</i> , 2020, 301, 163-166.	1.7	21
16	Genetic polymorphisms associated with telomere length and risk of developing myeloproliferative neoplasms. <i>Blood Cancer Journal</i> , 2020, 10, 89.	6.2	20
17	Serological response following BNT162b2 anti-SARS-CoV-2 mRNA vaccination in haematopoietic stem cell transplantation patients. <i>British Journal of Haematology</i> , 2022, 196, 928-931.	2.5	20
18	A Comparison of the Conditioning Regimens BEAM and FEAM for Autologous Hematopoietic Stem Cell Transplantation in Lymphoma: An Observational Study on 1038 Patients From Fondazione Italiana Linfomi. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1814-1822.	2.0	18

#	ARTICLE	IF	CITATIONS
19	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. <i>Annals of Hematology</i> , 2019, 98, 2329-2338.	1.8	17
20	A supervised CAD to support telemedicine in hematology. , 2015, , .		12
21	The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: Real-world data. <i>European Journal of Haematology</i> , 2020, 105, 3-15.	2.2	12
22	Outcome of Patients with Myelofibrosis after Ruxolitinib Failure: Role of Disease Status and Treatment Strategies in 214 Patients. <i>Blood</i> , 2018, 132, 4277-4277.	1.4	11
23	Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. <i>Annals of Hematology</i> , 2019, 98, 1885-1890.	1.8	10
24	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. <i>Annals of Hematology</i> , 2019, 98, 889-896.	1.8	10
25	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. <i>Annals of Hematology</i> , 2020, 99, 1525-1530.	1.8	9
26	Chronic myeloid leukaemia with extreme thrombocytosis at presentation: incidence, clinical findings and outcome. <i>British Journal of Haematology</i> , 2018, 181, 267-270.	2.5	8
27	Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine kinase inhibitors. <i>Hematological Oncology</i> , 2021, 39, 401-408.	1.7	8
28	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. <i>British Journal of Haematology</i> , 2018, 183, 35-46.	2.5	7
29	Do myeloproliferative neoplasms and multiple myeloma share the same genetic susceptibility loci?. <i>International Journal of Cancer</i> , 2021, 148, 1616-1624.	5.1	7
30	What Is New in the Treatment of Smoldering Multiple Myeloma?. <i>Journal of Clinical Medicine</i> , 2021, 10, 421.	2.4	7
31	Bosutinib in the Real-Life Treatment of Chronic Phase Chronic Myeloid Leukemia (CML) Patients Aged > 65 Years Resistant/Intolerant to Frontline Tyrosine-Kinase Inhibitors. <i>Blood</i> , 2019, 134, 1649-1649.	1.4	7
32	Dasatinib first-line: Multicentric Italian experience outside clinical trials. <i>Leukemia Research</i> , 2016, 40, 24-29.	0.8	6
33	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. <i>Blood Cancer Journal</i> , 2020, 10, 66.	6.2	6
34	Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study). <i>Frontiers in Oncology</i> , 2022, 12, 835563.	2.8	6
35	Use of tyrosine kinase inhibitors in a patient with Brugada syndrome and chronic myeloid leukemia. <i>International Journal of Hematology</i> , 2013, 98, 483-486.	1.6	4
36	Onset of chronic myeloid leukemia with complex karyotype in a pregnant patient: case report and revision of literature. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 751-755.	2.0	4

#	ARTICLE	IF	CITATIONS
37	MYC Rearranged Aggressive B-Cell Lymphomas: A Report on 100 Patients of the Fondazione Italiana Linfomi (FIL). <i>HemaSphere</i> , 2019, 3, e305.	2.7	4
38	Switching from dispersible to film coated tablet formulation of deferasirox improves hemoglobin levels and transfusional interval in patients with transfusionâ€dependentâ€thalassemia. <i>British Journal of Haematology</i> , 2020, 189, e60-e63.	2.5	4
39	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. <i>Hematological Oncology</i> , 2019, 37, 418-423.	1.7	3
40	Compound BCR-ABL1 Kinase Domain Mutants: Prevalence, Spectrum and Correlation with Tyrosine Kinase Inhibitor Resistance in a Prospective Series of Philadelphia Chromosome-Positive Leukemia Patients Analyzed By Next Generation Sequencing. <i>Blood</i> , 2018, 132, 789-789.	1.4	3
41	Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by ABO blood group in subjects with transfusion-dependent thalassemia.. <i>Acta Biomedica</i> , 2022, 93, e2022134.	0.3	3
42	A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3692.	2.4	2
43	Erythropoietin treatment in chronic phase chronic myeloid leukemia patients treated with frontline imatinib who developed late anemia. <i>European Journal of Haematology</i> , 2020, 105, 286-291.	2.2	2
44	Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor. <i>Frontiers in Oncology</i> , 2021, 11, 716751.	2.8	2
45	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. <i>Acta OncolÃ³gica</i> , 2021, 60, 1527-1533.	1.8	2
46	â€œHemolysis, or not Hemolysis, that is the questionâ€: Use of hydroxychloroquine in a patient with COVID-19 infection and G6PD deficiency.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2020, 12, e2020076.	1.3	2
47	SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma. <i>Blood Cancer Journal</i> , 2021, 11, 201.	6.2	2
48	A voluminous mass as an initial clinical symptom of multiple myeloma: A case report. <i>Experimental and Therapeutic Medicine</i> , 2015, 10, 1689-1691.	1.8	1
49	Favorable outcome of chronic myeloid leukemia coâ€expressing e13a2 and e14a2 transcripts, treated with nilotinib. <i>Hematological Oncology</i> , 2020, 38, 607-610.	1.7	1
50	Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Ponatinib in the Real-Life Practice: Prophylaxis and Identification of Risk Factors. <i>Blood</i> , 2018, 132, 3006-3006.	1.4	1
51	Long-Term Outcome Of Higher-Risk MDS Patients Treated With Azacitidine: Single Centre Experience. <i>Blood</i> , 2013, 122, 5220-5220.	1.4	1
52	Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. <i>Blood</i> , 2010, 116, 2294-2294.	1.4	1
53	Association between Proteomic Profile and Molecular Response (MR) in Chronic Myeloid Leukemia (CML) Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, S312.	0.4	0
54	Association between proteomic profile and molecular response in chronic myeloid leukemia patients. <i>Leukemia and Lymphoma</i> , 2018, 59, 1016-1018.	1.3	0

#	ARTICLE	IF	CITATIONS
55	Who seeks finds. Gaucher's disease: a rare case of thrombocytopenia. International Journal of Hematology, 2020, 111, 327-328.	1.6	0
56	Occurrence of chronic myeloid leukemia in a patient with <i>CDC73</i> gene deletion: "Chance or Causality?" International Journal of Laboratory Hematology, 2021, 43, e284-e286.	1.3	0
57	The Role of CD27, CD40 and CD117 in the Diagnosis and Prognosis of Multiple Myeloma Established by Flow Cytometry. Blood, 2014, 124, 5711-5711.	1.4	0
58	Impact of Proteomic Profile of Peripheral Blood and Bone Marrow Sera on Molecular Response in Patients with Chronic Myeloid Leukemia: Preliminary Data. Blood, 2014, 124, 5515-5515.	1.4	0
59	Cancer Associated Fibroblasts in Multiple Myeloma: The Urokinase Receptor System in Tumor Growth Regulation. Blood, 2014, 124, 5687-5687.	1.4	0
60	Young CML Patients Treated Frontline with Imatinib or Second Generation TKIs: Clinical Characteristics and Outcome. Blood, 2016, 128, 3078-3078.	1.4	0
61	Presentation and Outcome of 199 Patients with 2016 WHO Diagnosis of Early and Overt Primary Myelofibrosis Treated with Ruxolitinib. Blood, 2018, 132, 3052-3052.	1.4	0
62	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. Blood, 2019, 134, 4166-4166.	1.4	0
63	Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma. Acta Biomedica, 2021, 92, e2021205.	0.3	0